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Abstract
Human onchocerciasis—commonly known as river blindness—is one of the most devastating yet
neglected tropical diseases, leaving many millions in Sub-Saharan Africa blind and/or with
chronic disabilities. Attempts to eliminate onchocerciasis, primarily through the mass drug
administration of ivermectin remains challenging and has been heightened by the recent news that
drug-resistant parasites are developing in some populations after years of drug treatment. Needed,
and needed now, in the fight to eliminate onchocerciasis are new tools, such as preventive and
therapeutic vaccines. This review summarizes the progress made to advance the onchocerciasis
vaccine from the research lab into the clinic.
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Why a vaccine against Onchocerca volvulus is needed
Human onchocerciasis caused by Onchocerca volvulus and spread by the bite of infected
Simulium black flies (Figure 1) remains one of the most important neglected tropical
diseases (NTDs). Recent estimates from the Global Burden of Disease Study 2015 indicate
that approximately 15.5 million people currently live with onchocerciasis, including 12.2
million people with Onchocerca skin disease (OSD) and 1.025 million with vision loss (river
blindness) [1]. Almost everyone severely affected with OSD and river blindness lives in SubSaharan Africa or Yemen in the Middle East.
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Through programs of mass drug administration (MDA) with ivermectin, tremendous strides
have been made in reducing the global prevalence of onchocerciasis. Transmission has been
nearly eliminated in Latin America, while globally there has been a 29 percent reduction in
the prevalence of onchocerciasis since 2005 [1]. However, it remains unlikely that
onchocerciasis can be eliminated as a public health problem entirely through ivermectin
mass treatments. The reasons for this observation have been reviewed recently, and include
the inability to implement large-scale treatment programs in areas that are co-endemic for
loiasis, and the potential for emerging anthelminthic drug resistance [2]. Recent genomewide analyses revealed significant genetic variation in O. volvulus parasites, differentiating
between those that are good responders to ivermectin treatment and those that are suboptimal responders. Those parasites that responded sub-optimally were taken from
individuals in Ghana and Cameroon who experienced repopulation of the skin microfilariae
earlier/more extensively than expected after ivermectin treatment [3].
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In addition, disease modeling studies show that transmission interruption and elimination
will require routine and regular quantum reductions in O. volvulus microfilariae in the skin
and subcutaneous tissues following each round of MDA, but such targets are seldom
achieved [2]. The African Programme for Onchocerciasis Control predicted in 2015 that to
achieve elimination 1.15 billion treatments will have needed to be administered until 2045
[4]. Such estimates indicate that onchocerciasis may not be eliminated for decades using
current approaches.
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To accelerate elimination and advance towards the major targets of the 2012 London
Declaration for NTDs (http://unitingtocombatntds.org/sites/default/files/document/
london_declaration_on_ntds.pdf), there is an effort to develop new and improved control
tools. These include better diagnostics, small-molecule drugs and vaccines that can improve
surveillance and achieve longer and more sustained reductions in host microfilarial loads.
There is also a need for better safety profiles for interventions used in loiasis co-endemic
areas of Africa. Individuals who have high blood levels of Loa loa microfilariae, a filarial
infection that usually does not cause clinical disease, and receive ivermectin as part of the
MDA programs to eradicate lymphatic filariasis and onchocerciasis, may develop a severe
inflammatory reaction that can result in encephalopathy, and rarely death. In 2015, an
international consortium launched a new global initiative, known as TOVA – The
Onchocerciasis Vaccine for Africa [2]. TOVA is evaluating and pursuing vaccine
development as a complementary control tool. Briefly, TOVA is primarily using recombinant
proteins and novel adjuvant platforms, with the goal to meet at least one of the desired target
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product profiles (TPP). The TPP either relies on a preventive vaccine for children under the
age of five who have not yet had access to MDA with ivermectin, or a therapeutic vaccine
for both adults and children with onchocerciasis (Table 1) [2]. The efforts to develop an
effective, safe, and logistically feasible vaccine against onchocerciasis builds on the
evidence of protective immunity achieved using live attenuated vaccines. Immunization with
irradiated larvae typically achieves ~70% protection in laboratory settings [5–9], but such
vaccines are not feasible for mass human immunization on safety, logistical, and economic
grounds. Current efforts to develop a subunit vaccine, such as confirmatory vaccine trials in
large-animal models, modeling studies, and future clinical trials will build the necessary
body of evidence to allow for the selection of the best TPP. The TPP presented in Table 1
was based in part on mathematical modelling that explored the potential influence of a
prophylactic vaccination program on infection resurgence in areas where local elimination
has been successfully achieved [10]. It assumed an initial prophylactic efficacy of 50% and
an initial therapeutic efficacy of 90%, based on efficacy results in animal models. The
vaccine was assumed to target 1 to 5 year olds based on the age range included in the
Expanded Programme on Immunization. The modelling indicated that an onchocerciasis
vaccine would have a beneficial impact in onchocerciasis-loiasis co-endemic areas,
markedly reducing microfilarial load in the young (under 20 yr) age groups. The TPP for
therapeutic vaccines is still hypothetical as it assumes that it will be safe to target
immunologically residual microfilariae in young and adult populations living in endemic
regions that went through many years of MDA with ivermectin.

Author Manuscript

Here, we provide a perspective of the importance of a rational design for the discovery and
antigen selection process before embarking into advanced vaccine development of the
onchocerciasis vaccine with a review of the current advancements and progress on the
TOVA global initiative. Finally, we provide a prospective of how new technologies and
artificial intelligence can catalyze and accelerate the evaluation and selection of suitable
vaccine candidates leading to a greater chance of their translation into safe and efficacious
human vaccines.

Discovery and evaluation of the first generation vaccine candidate antigens
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Considerable effort has been expended in the 1990s on the identification of parasite
molecules, primarily proteins, which induce a protective immune response in humans and in
the available animal models of onchocerciasis. Anti-L3 protective immunity within the O.
volvulus endemic population has been described in two populations: (1) immunity that
impedes the development of a patent infection (microfilaria positive) in putatively immune
(PI) individuals (i.e., individuals that had no clinical manifestations of the disease, even
though they lived for at least 10 years within regions where onchocerciasis is endemic and
were exposed to high transmission rates of infection); and (2) concomitant immunity, which
develops in the patently infected individuals with increasing age and is independent of the
immune responses that are induced by the adult worms and microfilaria associated with
patent infection [11]. Protective immunity against the infective larvae was also shown in a
mouse model employing O. volvulus L3 in diffusion chambers; a significant reduction of
~50% in the survival of larvae was obtained in mice immunized with normal, irradiated or
freeze-thaw-killed L3 [5].
Trends Parasitol. Author manuscript; available in PMC 2019 January 01.
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Two basic strategies were used to identify and clone O. volvulus target vaccine antigens: (1)
Exploitation of the potential involvement of antibodies in protective immunity by
immunoscreening various O. volvulus cDNA libraries to identify target proteins. The
success of the immunoscreening effort relied mostly on the source and specificity of the
immune sera from human or animal hosts and, hence, was done mostly with serum samples
from individuals identified as putatively immune. In addition, sera from vaccinated or
immune animals (chimpanzees, mice or cows), polyclonal antibodies raised against O.
volvulus infective stage larvae also called L3, or monoclonal antibodies developed against
specific parasite-antigens, were used to screen the cDNA libraries. Initially cDNA libraries
constructed from adult worm stages of O. volvulus were used and later cDNA libraries
constructed from O. volvulus larval stages (L3, molting L3 and fourth-stage larvae or L4)
were used. Altogether, out of 26 recombinant antigens that were identified by
immunoscreening and tested in the O. volvulus mouse model, 12 induced partial but
significant protection (39–69%) in the presence of block copolymer, alum or Freund’s
complete adjuvant [11–13]. (2) Identification and isolation of molecules thought to be
essential during the infection process. These molecules would include proteins with vital
metabolic functions or defense properties, which would permit the parasite to survive in
immunocompetent hosts. Targeting such molecules as vaccine candidates, would block or
interfere with the establishment of the parasite in the host. In addition, antigens that are not
normally seen by the host, but that are nevertheless accessible to host immune-effector
molecules and cells, the ‘hidden antigens’, were also thought to be potentially useful as
vaccine targets [14]. The identification of the genes and isolation of the encoding proteins of
interest was achieved by one or multiple of the following methods: a) screening cDNA
libraries using a heterologous probes [15]; b) amplification by PCR using degenerate
primers and cloning strategies [15]; c) purification of the proteins from secreted products of
larval stages followed by partial amino acid sequencing and molecular cloning [16]; or d)
identification of the genes of interest by searching the O. volvulus expressed sequence tag
(EST) database or the EST databases generated by the Filarial Genome Project [17]. Out of
18 recombinant antigens that have been cloned using these strategies and that were tested in
the O. volvulus mouse model, four (Ov-ALT-1, Ov-CHI-1, Av-ABC and Av-UBI) induced
partial but significant protection. Of these, Av-ABC and Av-UBI were cloned from the
rodent filarial parasite Acanthocheilonema viteae and were protective in the presence of
alum or Freund’s complete adjuvant, as was Ov-ALT-1. In addition, chitinase, Ov-CHI-1,
effectively induced protection using DNA immunization [18]. The Onchocerca homologue
of Av-ABC has not been studied yet, whereas the Av-UBI of A. viteae is completely
identical to Ov-UBI.
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The characteristics of the parasite proteins corresponding to the above protective
recombinant O. volvulus antigens have been described in detail previously [12, 13, 19].
Eight of the proteins, Ov-ALT-1, Ov-B8, Ov-RAL-2, Ov-B20, OI5/OI3, Ov-CHI-1, OvRBP-1 and Ov-103 are parasite specific antigens, whereas Ov-ASP-1 is a member of the
vespid venom allergen-like protein family [20]. Six of the protective proteins are
homologues to recognized proteins of higher organisms. Thus, Ov-CPI-2 (onchocystatin),
Ov-TMY-1 (tropomyosin), Ov-FBA-1 (aldolase), Ov-CAL-1 (calponin), Av-ABC (ATP
binding cassette protein transporter) and Av-UBI (ubiquitin) have 32, 31, 69, 42, 71 and
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98% amino-acid identity, respectively, with human proteins. An important concern
associated with vaccine antigens belonging to conserved gene families (e.g. enzymes,
muscle proteins) is the risk of cross-reactions with host or environmental antigens. Eight
antigens were also cloned from a very close relative of O. volvulus, O. ochengi, and used
together to vaccinate cattle in the only field trial of a recombinant onchocerciasis vaccine
performed to date [21]. These eight antigens included representatives from the parasitespecific [Oo-ALT-1, Oo-B8, Oo-RAL-2, Oo-B20 and Oo-FAR-1 (homolog of Ov-RBP-1)]
as well as the highly conserved (Oo-TMY-1 Oo-FBA-1, and Oo-CPI-2) protein groups. The
multivalent vaccine induced statistically significant protection also against patency
(microfilaridermia), but did not significantly reduce adult worm burden [22].
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Since the above described studies, only one additional antigen with protective properties,
Ov-GAPDH, which was cloned using immunoscreening, has been recently reported [23].
Thus, out of a total of 16 vaccine candidates, 12 were identified by immunoscreening and 4
were identified using other approaches as illustrated in Figure 2. Below we will describe the
8 vaccine candidates chosen to be studied in greater depth for their ability to insure
protection against infection.

Evaluation and selection of the best vaccine candidates for a prophylactic
vaccine using two small animal models
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Humans are the only definitive hosts of O. volvulus. Therefore, one of the significant
challenges towards the development of a vaccine against onchocerciasis has been the
absence of suitable small animal models that support the life-cycle of the parasite (Figure 1).
To overcome this obstacle, we adopted a dual-model screening system. In the first model, O.
volvulus L3 are implanted in mice within diffusion chambers [24]. This model has the
advantages of using the target human parasite and allows the unique analysis of the host
molecules and cells found within the parasite microenvironment. In addition, dissection of
the mechanism of immunity induced by the vaccine can be accomplished with the plethora
of reagents and assays designed for murine studies. A significant disadvantage of the mouse
diffusion chamber model is that the parasites will only develop for a limited time in mice
and thus adult worms and microfilariae do not develop. To overcome this limitation, we
tested in parallel a second system, the Brugia malayi-gerbil model of lymphatic filariasis,
using homologues of promising O. volvulus antigens. Injection of L3 subcutaneously in this
model allows for examination of vaccine efficacy following the natural migration of
developing stages of parasites and their maturation to adult stages [25].
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From the pipeline of potential candidate antigens (Figure 2), fifteen proteins were evaluated
in previous studies using the mouse-Onchocerca model and identified as being able to
induce partial protection following vaccination [13]. To select the most promising protective
antigens for the early pre-clinical process development, a scoring system was developed that
allowed ranking these 15 antigens based on their other known characteristics (reviewed in
[13]), and to select eight vaccinate candidate for more extensive studies. All the 15 O.
volvulus protective antigens in the O. volvulus - mouse model were given a score of 1.0
(Table 2). The added scoring was based on the following criteria: (1) score 0.2 was given to
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those that are nematode or parasite specific with or without known function (for example
Ov-CPI-2 (cystatin), Ov-RBP-1 (retinoid binding protein) or Ov-CHI-1 (chitinase); (2) score
0.2 was given to those in which localization of the corresponding native proteins in L3
and/or molting L3 (mL3) by immunoelectron microscopy was in one or more regions that
are also recognized by antibodies from protected humans and/or also from xL3 immunized
and protected mice [11]; (3) score 0.2 was given to those being recognized by antibodies
from protected humans (PI and INF with concomitant immunity) and/or animal models after
immunization with xL3 (cattle, chimpanzees, mice); (4) score 0.2 was given to those being
abundantly expressed in L3 and/or mL3, which indirectly indicates that the corresponding
translated proteins are important for the parasite during the initial phases of the Ov infection;
and (5) score 0.2 was given to those where studies have shown the ability of antibodies
targeting the parasite antigen to kill larvae in vitro.
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In addition, we have added two more criteria [45] that are based on more recent published
and unpublished studies and thus provide added support for the selection of these 8 antigens
for our proposed preclinical studies. A score of 1.0 was given to those (for examples OvALT-1, Ov-CPI-2, Ov-RAL-2, chitinase, Ov-RBP-1 and Ov-B20) whose homologues have
been shown to also induce protection in other filariae host–parasite systems [26–36].
Moreover, A score of 1.0 was given to those (Ov-ASP-1, Ov-103, Ov-CPI-2, Ov-RAL-2)
having homologues in other nematode host–parasite systems that have been shown to be
able to induce reduction in worm burden or other protective measures against hookworm
infection in dogs and Ascaris in pigs [37–44]. Based on this rational innovative scoring
system we have selected the top ranking 8 Ov protective antigens (Ov-CPI-2, Ov-ALT-1,
Ov-RAL-2, Ov-ASP-1, Ov-103, Ov-RBP-1, Ov-CHI-1 and Ov-B20) for which we propose
to conduct extensive preclinical evaluation and further selection. Those selected are ranked
between a total score of 4.0 to 2.6 (Table 2). Those of the original 15 rOvAgs that were not
selected were only ranked at a total score of 1.0 to 1.6.
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The eight selected O. volvulus proteins and the B. malayi homologues were expressed in
both bacterial (Escherichia coli) and eukaryotic (Pichia) expression systems. In the presence
of the adjuvant alum, the recombinant Ov-103 and Ov-RAL-2 proteins, together with their
Bm-103 and Bm-RAL-2 homologues emerged as the most promising candidates in each
animal model, validating the robustness of our selection and prioritization process.
Combination of these two antigens by either co-administration vaccine strategies or single
injections using a recombinant fusion protein vaccine induced enhanced levels of protective
immunity, demonstrating that the antigens could act synergistically in both systems [45, 46].
Furthermore, these co-administered molecules or the fusion proteins reduced embryogenesis
in B. malayi females, suggesting a potential impact also on microfilaremia and transmission
[46].
Various adjuvants were evaluated and compared for their ability to improve efficacy by
enhancing the killing of O. volvulus in diffusion chambers implanted in mice. Only
adjuvants that induced Th2 responses, as determined by cytokine profiles, were effective at
enhancing the vaccine efficacy, consistent with reports showing that IL-4, IL-5, and
functional eosinophils are necessary for the development of adaptive immunity in mice
immunized with irradiated O. volvulus larvae [47–49], and the Litomosoides sigmodontis
Trends Parasitol. Author manuscript; available in PMC 2019 January 01.
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murine model [50–54]. Co-administration of both of the O. volvulus antigens enhanced
parasite killing as compared to single antigen immunizations, with all of the adjuvants
inducing Th2 responses. Antigen specific IgG1 was the dominant antibody isotype that
developed in protected immunized mice. Based on chemokine levels within the diffusion
chambers, it appears that eosinophils, macrophages and neutrophils participate in the killing
mechanism. These findings suggest that the mechanism of protective immunity induced by
the two O. volvulus antigens is multifactorial with roles for cytokines, chemokines, antibody
and specific effector cells [55]. This observation was confirmed in the B. malayi–gerbil
model, where it was demonstrated that serum from gerbils immunized with the two B.
malayi antigens on alum, killed the parasites in vitro, in collaboration with peritoneal
exudate cells [46].
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Thus, based on the two model systems, O. volvulus in mice and B. malayi in gerbils, an
effective two-antigen vaccine against O. volvulus has been identified. It consists of the
proteins Ov-103 and Ov-RAL-2, administered with an adjuvant that induces Th2 responses.
Immunization with both antigens enhanced the protective immune response and the
mechanism of protective immunity appears to be antibody and effector cell dependent, in
both model systems.
As mentioned above, a third small-animal model, the L. sigmodontis-BALB/c mouse model,
has been developed and used for studying anti-filarial immunity and vaccines [56, 57]. This
model also allows full development of the infective larvae to adult worms producing
circulating microfilariae. It will be worthwhile to incorporate this third model into future
efficacy pipeline studies and validate the L. sigmodontis homologous of the O. volvulus
vaccine candidates also in this filarial infection model in mice.
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The need for a rational and efficient process to generate a robust pipeline
of second generation vaccine candidate antigens
The disappointing results obtained many times during human proof of concept clinical trials,
continue to highlight the challenges and limitations of how to best predict whether a vaccine
candidate translates successfully from animal testing into humans [58, 59].
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Many articles call for a change in paradigm from an empirical development strategy to a
rational vaccine design [60–62]. Amongst the parameters driving decisions during the
development of new vaccine targets, the current consensus is that antigen selection and
optimization represents the foundation in vaccine design. In addition, it is essential to have
available appropriate preclinical models, but it is also crucial to have optimal vaccine
formulations, adjuvants and delivery strategies. These are essential elements to target the
appropriate immune mechanisms of protection [63]. This is especially important when
developing vaccines for infectious diseases, such as for onchocerciasis, because
unfortunately scientific advances and tools are still trailing and there is also a need for safety
and efficacy studies to be done more quickly, with more certainty and at lower costs.
For example, strategies to identify the ideal Onchocerca vaccine candidate antigens can rely
on selection processes based on the knowledge of candidates inducing effective immune
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responses, identifying antibody-based epitopes via computational prediction tools, downselection of candidates based on predictions of sequences that could induce
immunopathology or allergy, and continuous assessment of parasite molecules by structural
biology and stability assessments. Hence, systems biology approaches continue to lead the
efforts seeking better understanding of the mechanisms of protection and safety of vaccines
[61].
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Considerable efforts have also been done in the area of novel adjuvant development. Subunit
vaccines need help with secondary molecules modulating the immune responses. TOVA
Initiative is also incorporating into the development path the evaluation of other adjuvants
besides the traditional phosphate or hydroxide salts of aluminum such as oil-in-water
emulsions and synthetic toll-like receptor agonists [62]. The objective is to select adjuvants
that facilitate the most effective response, while in parallel investigate their optimized use,
route and molecular mechanism.
Selecting and evaluating the ideal delivery route and system also provides a benefit towards
rational vaccine design. Investigating the mechanisms to overcome pre-existing immunity,
an understanding of the basis for the stimulation of memory responses, and examining the
interface between innate and adaptive immunity can also maximize the potential for vaccines
to trigger long-lasting immunity and protection.

Using ‘omics to catalyze and accelerate the decision process for the
discovery of second generation vaccine candidate antigens

Author Manuscript

Recent technology advancements of the 21st Century have allowed the use of new animal or
computer-based predictive models, biomarkers for safety and efficacy, and clinical
evaluation techniques to assist in the improvement of predictability and efficacy needed
along the critical path to move discoveries from the laboratory bench to licensure.
Ultimately, developing and identifying methods to establish correlate markers or surrogate
endpoints for protection will be necessary and essential [60].
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The current accumulation of molecular data and expansion of filarial parasite RNA and
DNA databases, as well as proteomic datasets, has already provided a fresh start by
permitting a more rational approach to vaccine candidate discovery [64]. For instance, the
availability of genomes for B. malayi, L. sigmodontis and O. ochengi has facilitated
numerous secretome studies across the parasite lifecycle [65–67]. One group of vaccine
candidates that was identified by this unbiased, high-throughput approach was a ShK toxin
domain family in which each individual member contains six ShK domains; a situation that
is unique to filarial nematodes [30]. These abundant secreted proteins probably have an
immunomodulatory role [66, 68] that could be targeted using antigens incorporating rational
mutation of critical amino acid residue(s); an approach that has been used successfully with
CPI-2 [56, 69]. In addition, the O. volvulus genome, as well as the transcriptome and
proteome of each stage from the definitive host (L3, molting L3, L4, adult male, adult
female, and nodule and skin microfilaria stages), has been published recently [70, 71]. These
new datasets, when combined with immunomics [72–76], have provided an opportunity to
identify the antigens that, either alone or in combination, function as targets of natural
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acquired immunity against filariae. Recombinant protein or synthetic peptide arrays can be
used to interrogate the genome-wide proteome of infectious pathogens consisting of the
entire potential antigens using only small amounts of individual sera samples. This approach
permits investigators to perform extensive longitudinal, epidemiological and surveillance
analyses, as well as identifying immune responses at various stages of infections in the
human host in a fashion not possible with other technologies [77, 78].
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Using the immunomics approach with sera samples from putatively immune individuals
from Cameroon and the Americas versus sera from infected individuals, six new potential
vaccine antigens were identified. This was accomplished by screening for IgG1, IgG3 and
IgE antibody responses against a protein array containing 362 O. volvulus recombinant
proteins [71], and identifying those with a significant IgG1 and/or IgG3 reactivity with littleto-no IgE reactivity. Notably, four of these antigens (OVOC10819, OVOC5395,
OVOC11598 and OVOC12235) are highly expressed during the development of the early
stages of the infective stage larvae, L3, in the human host; these would be worthy candidates
for testing their efficacy in a preventative vaccine model of infection. Interestingly, the two
other proteins (OVOC8619 and OVOC7083) are highly expressed by the microfilariae and
were mostly recognized by sera from the putatively immune individuals who never
developed a patent infection with microfilaridermia; these would be worthy to be tested as
vaccine candidates for a therapeutic vaccine [71].
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The initial objective for the Onchocerca vaccine was to identify candidate antigens for a
prophylactic vaccine to be administered to children under the age of five who have not yet
had access to MDA with ivermectin (Table 1); the first generation of our vaccine candidates
fulfilled this objective. However, the immunomics approach now opens new possibilities for
also developing a safe anti-transmission or therapeutic vaccine. The immunomics studies
reported by Bennuru et al. [71] were the first time in which the O. volvulus stage-specific
genome-wide expression data was used to discover empirically novel vaccine candidates. It
would be of great interest to test the novel vaccine candidates identified by the immunomics
approach [71] in the O. volvulus diffusion chamber mouse model [45] and B. malayi – gerbil
infection model to validate whether the immunomics approach actually have identified
vaccine candidates that protect against L3 and/or microfilariae.
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Other potential applications of immunomic approaches include unbiased characterization of
the immune response at the site of infection. In the O. ochengi system in cattle, a recent
secretome analysis of nodule fluid identified almost 500 host proteins that ‘bathe’ the adult
worms in vivo [67]. Interestingly, these proteins were dominated by antimicrobial proteins,
such as cathelicidins, which probably originate from the neutrophils that dominate the
intranodular environment. A parallel approach could be used to explore the immunological
changes that occur within nodules in animals displaying partial protection induced by
vaccination. Such studies will be very valuable in the future for the machine learning
approach described below.
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Prospective: The potential for machine learning to accelerate the evaluation
and selection of vaccine candidates
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Decades of research on prototype anti-filarial vaccines in animal models, the application of
transgenic knockout mouse strains, and immunological studies of onchocerciasis patients
presenting different clinical phenotypes, has led to a broad consensus on the characteristics
of protective immunity and some of the key factors that drive immunopathology. Thus, a
Th2-biased immune response directed against incoming infective larvae, with a secondary
(but important) role for a Th1 component and the modulating influence of T-regulatory cells,
is associated with ‘benign’ protection [57, 79, 80]. Conversely, at least in humans,
unregulated Th2 responses against microfilariae in conjunction with Th17-driven
inflammation and profound eosinophilia lead to effective parasite killing, but at the price of
a hyperreactive form of onchocerciasis exhibiting severe skin inflammation also called
sowda if the inflammation is unilaterally predominant [81, 82]. This very rare condition is
associated with certain genetic polymorphisms in immune-related genes [83, 84]. However,
adverse reactions with a clear immunological component are possible in a wider range of
patients, as is not uncommon with antifilarial chemotherapy [85, 86]. Consequently,
accurately predicting whether a vaccine candidate is likely to be both safe and effective is
very challenging using conventional approaches alone, especially as we lack animal models
that recapitulate the pathology seen in human onchocerciasis.
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Traditional statistical approaches can be powerful at disentangling these immunological
events, but tend not to generalize well from model systems to humans. However, machine
learning techniques have been developed to improve generalizability by tuning models to
maximize prediction accuracy to independent test samples, and tend to deal with large
numbers of variables better than traditional statistical approaches [87, 88]. Such methods
have been used successfully to analyze immune responses to bacterial infection using whole
blood transcriptional signatures [89], and to detect local pathogen-specific immune profiles
in peritoneal dialysis patients [87]. In principle, by combining vaccinology read-outs from
animal models and natural immunity in humans, it may therefore be possible to improve the
selection of vaccine candidates earlier than currently possible. Thus, by identifying robust
markers of immunity that generalize well, such approaches may help bridge the divide
between development, preclinical, and clinical phases of vaccine development (Figure 3).

Concluding remarks
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Although it was previously considered that O. volvulus infections can be controlled using
only MDA with ivermectin, it is becoming increasingly clear that without additional
modalities such as drugs which kill or permanently sterilize the adult worms and/or a
vaccine, elimination of onchocerciasis from Sub Saharan Africa may remain an unfulfilled
goal. Vaccines aimed at preventing infection (anti-L3), and/or reduce microfilariae in adults
and children with onchocerciasis could be the essential complement for the successful
control or elimination of both diseases.
The successful vaccines developed against taeniases and the major advances already made in
development of human anthelminthic vaccines [90], show that it is indeed possible to
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develop and test protective vaccines against multicellular parasites. In regard to O. volvulus,
the human studies have suggested that protective immunity can develop in humans. The
experimental and natural infections of calves have demonstrated that protective immunity
does develop and that vaccines can protect animals from infection under natural conditions.
Moreover, using the small animal models for antigen screening have already accomplished
the identification of two lead vaccine candidates; now the challenge is to optimize and
formulate these vaccines for human usage, which can take advantage of the procedures
currently being developed for the human hookworm and schistosome vaccines [91, 92],
making the process potently quicker than usually expected (see Outstanding Questions).
Efforts to develop novel diagnostic assays that support the monitoring of current and future
control measures are underway and are expected to soon provide diagnostic assays that can
predict efficacy of the prophylactic and therapeutic vaccines in human clinical trials.
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Outstanding Questions
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•

What additional tools are needed to support the elimination of onchocerciasis
in Africa?

•

Adjuvants are an important component for vaccine delivery; additional
adjuvants that may increase efficacy. Should other adjuvants be tested versus
the alum formulated vaccines?

•

Should we optimize the O. volvulus vaccine in regard to dosage, number of
immunization and ability to provide sufficient memory?

•

Should we proceed to identify new vaccine candidates for prophylactic and/or
therapeutic vaccines using more rational approaches?

•

How can new technologies and artificial intelligence catalyze and accelerate
the evaluation and selection of more effective vaccine candidates leading to a
greater chance of their translation into safe and efficacious human vaccines?

•

Can we develop diagnostic assays that can predict efficacy of the prophylactic
and therapeutic vaccines in human clinical trials?

The task ahead is to assure continued pre-clinical development by convincing potential
donors that O. volvulus vaccine production and testing is a realistic goal worth supporting.
The potential development of drug resistance to the drugs used for MDA and the many years
of MDA now being anticipated to control onchocerciasis might provide such impetus.
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Box 1
Key points that support the advancement and progress towards an
onchocerciasis vaccine
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•

It remains unlikely that onchocerciasis can be eliminated entirely through
ivermectin mass treatments

•

An international consortium launched in 2015 a new global initiative, known
as TOVA – The Onchocerciasis Vaccine for Africa – with the goal of
evaluating and pursuing vaccine development as a complementary control
tool

•

A rational design for the antigen discovery and selection process before
embarking into advanced vaccine development of the onchocerciasis vaccine
resulted in the identification of two recombinant proteins – Ov-103 and OvRAL-2 – that individually or in combination induced significant protection
against infection
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Figure 1.

Author Manuscript

The Onchocerca volvulus lifecyle. During a blood meal, an infected blackfly (genus
Simulium) introduces third-stage filarial larvae onto the skin of the human host, where they
penetrate into the bite wound ➊. In subcutaneous tissues the larvae ➋ develop into adult
filariae, which commonly reside in nodules in subcutaneous connective tissues ➌. Adults
can live in the nodules for approximately 15 years. Some nodules may contain numerous
male and female worms. Females measure 33 to 50 cm in length and 270 to 400 μm in
diameter, while males measure 19 to 42 mm by 130 to 210 μm. In the subcutaneous nodules,
the female worms are capable of producing microfilariae for approximately 9 years. The
microfilariae, measuring 220 to 360 μm by 5 to 9 μm and unsheathed, have a life span that
may reach 2 years. They are occasionally found in peripheral blood, urine, and sputum but
are typically found in the skin and in the lymphatics of connective tissues ➍. A blackfly
ingests the microfilariae during a blood meal ➎. After ingestion, the microfilariae migrate
from the blackfly’s midgut through the hemocoel to the thoracic muscles ➏. There the
microfilariae develop into first-stage larvae ➐ and subsequently into third-stage infective
larvae ➑. The third-stage infective larvae migrate to the blackfly’s proboscis ➒ and can
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infect another human when the fly takes a blood meal ➊. Reproduced from the Center for
Disease (https://www.cdc.gov/dpdx/onchocerciasis/index.html).
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Figure 2.

Schematics that illustrates the down-selection process that resulted in the selection of the
two most promising vaccine antigens for future clinical development.
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Figure 3.

Author Manuscript

Combining a systems analysis of response to vaccines and machine learning algorithms to
help predict vaccine efficacy. (A) Applying machine learning to experimental infections
across multiple model systems and species can help identify which immune variables
throughout the time course of an infection most reliably predict infection load, while
ensuring the trained models generalize well across biological systems. (B) These optimized
models may then be useful in predicting vaccine efficacy in human trials in two ways:
identifying what data to collect and predicting likely vaccine efficacy using incomplete data
that are typical of human field studies.
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Intramuscular injection
Single-dose vials; <0.5 ml volume of delivery
Maximum of 3 immunizations given 4 weeks apart
Mild to moderate local injection site reactions such as erythema, oedema and pain, the character, frequency, and severity of
which is similar to licensed recombinant protein vaccines. Less than 0.01% risk of urticaria and other systemic allergic
reactions. Incidence of serious adverse reactions no more than licensed comparator vaccines
>50% efficacy at preventing establishment of incoming worms; >90% reduction of microfilariae (based on current animal
model results)
All doses may be co-administered and/or used with other infant immunization programmes
4 Years
Refrigeration between 2 to 8 degrees Celsius. Cannot be frozen. Can be out of refrigeration (at temperatures up to 25
degrees) for up to 72 hours
Licensure by the Food and Drug Administration and/or the European Medicine Agency
Less than $10 per dose for use in low- and middle-income countries.

Route of administration

Product presentation

Dosage schedule

Warnings and precautions/
pregnancy and lactation

Expected efficacy

Co-administration

Shelf life

Storage

Product registration

Target price

the assumptions for the blank cells are similar to those expected for the prophylactic vaccine

b

adapted from [2].

a

Children <5 years

>99% reduction of microfilariae

older children and adults that
already carry adult worms

A vaccine to reduce
microfiladermia for the purpose
of reducing morbidity and
transmission

A vaccine to protect against infection with infective larvae and to reduce adult worm burden and microfiladermia for the
purpose of reducing morbidity and transmission

Indication

Target population

Desired target – therapeutic (if
different)b

Desired target – prophylactica

Characteristic

Target product profiles for prophylactic and therapeutic onchocerciasis vaccines
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Granules of
glandular
esophagus; ES

Novel, homologue of
vespid venom allergen 5
and the PR-1 protein
family

0.2

Novel, nematode specific

Ov-ASP-1 (25)

Score

Ov-RAL-2 (17)

Hypodermis

0.2

0.2

0.2

Score

Hypodermis;
basal layer of
cuticle;
separation of
L3/L4
cuticles;
secretory
vesicles; ES

Localizationb

Onchocystatin, (Cysteine
protease inhibitor)

Identity (Function)

Ov-CPI-2 (17)

Antigen (kDa)

PI sera
CI sera
Mouse anti-OvxL3

0.2

PI sera
CI sera
Mice anti-Ov-xL3

0.2

PI sera
CI sera
Chimpanzee antiOv-xL3

Immunogenicityc

Characteristics of the O. volvulus protective protein

6/4

0.2

50/1

0.2

59/9

#ESTsd
L3/mL3

1

51–60 % (FCA)

Anti-rAs16
from the
protected
pigs inhibit
survival and
molting of
L3 in vitro

44 % (alum)
42% (FCA)

1

43–49% (alum)

Protection in
Ov mouse
model (%)e
[adjuvant]

1
rAs16;
64%
reduction
in A. suum
L3 [mice,
cholera
Toxin
(CT)]

rWb-SXP/Bm14;
30% reduction of
L3 survival within
chambers [mice,
FCA]
Wb-SXP; 19%
reduction of L3
survival within the

Ac-ASP-2;
26%
reduction
in worm
burden;
69%
reduction
in eggs
output;
serum
from the
vaccinated
dogs
induced in
vitro 60%
reduction
in L3
migration
[Ac dog
model,
AS03]

1

Accystatin;
22%
reduction
in worm
burden [Ac
dog model,
AS03]

Protection
in other
helminth
models
(model,
adjuvant)

1

Bm-ASP-1; 62%
reduction in
survival of L3 in
chamber [jird,
alum]
Bm-ASP-1+BmALT-2 +; 79%
reduction in worm
burden [jird, alum]

1

Ls-cystatin; 50%
reduction in patent
infectionf [Ls
mouse model, alum
and Pam3Cys]

Protection in
lymphatic filariae
models [animal
model, adjuvant]

Protection in animal models

0.2

in vitro
against Bm
L3 and Mf

Serum from
jirds
immunized
with BmASP-1
caused 62%
cytotoxicity

0.2

96–100%
inhibition
of Ov L3
molting

In vitro
killing
assayse
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The portfolio of eight lead O. volvulus protective larval proteinsa
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3.8

4

4

Total Score
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0.2

Novel, nematode specific

Ov-103 (15)

Novel, filariae specific

0.2

Identity (Function)

Score

Ov-ALT-1 (15)

Score

Author Manuscript

Antigen (kDa)

In L3: Basal
layer of the
cuticle;
hypodermis;
basal lamina;
channels;
multivesicular
bodies.

0.2

Granules of
glandular
esophagus;
cuticle;
channels

0.2

Localizationb

PI sera
CI sera

PI sera
CI sera

0.2

0.2

Immunogenicityc

5/0

0.2

223/18

0.2

AntiOv-103
killed Mf
79%

0.2

in vitro

Serum from
jirds
immunized
with BmALT-2
caused 72%
cytotoxicity
against Bm
L3 and Mf

In vitro
killing
assayse

30–69 % (alum)

1

39–62% (alum)

1

Protection in
Ov mouse
model (%)e
[adjuvant]

Author Manuscript
#ESTsd
L3/mL3

NDg

AcSAA-1;
antibodies
inhibited
(46%)
migration
of L3 [Ac,
FCA]

ALT-1 is a
filariae
specific
protein

Bm-ALT-1; 76%
reduction in worm
burden [jird, FCA]
Bm-ALT-2; 72%
reduction in
survival of L3 in
chamber [jird,
alum]
Bm-ALT-2 + BmASP-1; 79%
reduction in worm
burden [jird, alum]
1

1

rAs16;
58%
reduction
in A. suum
lung –
stage L3s
[pigs, CT]
rAc-16;
25%
reduction
in
hookworm
worm
burden,
64%
reduction
in egg
count and
significant
reduction
of blood
loss [dogs;
AS03]

Protection
in other
helminth
models
(model,
adjuvant)

1

chambers [mice,
DNA]
rBm-SXP-1; >90%
reduction in
microfilaremia and
35% in adult worm
burden [jirds, FCA
or Alum]

Protection in
lymphatic filariae
models [animal
model, adjuvant]

Protection in animal models
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3.0

3

Total Score
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Chitinase

0.2

Cuticle,
granules of
glandular
esophagus

0.2

0.2

0.2

PI sera
CI sera
Jird anti-Av-xL3

PI sera
CI sera

0/0

0.2

1/2

0.2

3/2

0.2

ND

ND

ND

0.2

1

53% [DNA]

1

42 % [BC]

1

39 % [Alum];

1

Protection in
Ov mouse
model (%)e
[adjuvant]

1

Bm-chitinase;
induced 48%
reduction in worm
burden and >90%
in Mf [jirds, FCA
and alum]

1

36–55% [Av, FCA]

1

49–60% [Av, FCA]

Protection in
lymphatic filariae
models [animal
model, adjuvant]

ND

ND

ND

1

Protection
in other
helminth
models
(model,
adjuvant)

2.6

2.8

2.8

Total Score
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Protection was determined in mice after two immunization with 25 μg of protein in the presence of an adjuvant or using a DNA vaccine, followed by challenge with 25 L3 within diffusion chambers, and is
defined by a significant (p<0.05) % of reduction of L3 survival in the immunized mice vs. control mice.

g

Using in vitro cytotoxicity assays few antigens were shown to be a target for antibodies raised against the recombinant antigens of Ov-CPI-2 and Ov-103. Although antibodies against the other vaccine
candidates were not tested in vitro for their ability to inhibit molting or kill larvae, it appeared that immunization with the recombinant antigens Ov-CPI-2 and Ov-ALT-1 also induced significant reduction
in the molting of L3. Moreover, studies using antibodies from mice immunized with the B. malayi homologous recombinant proteins of Ov-ALT-1 (Bm-ALT-2) and Ov-ASP-1 (Bm-ASP-1) have shown that
anti-Bm-ALT-2 antibodies elicited 71–72% cytotoxicity in vitro against both L3 and Mf, while anti-Bm-ASP-1 antibodies induced 61–62% cytotoxicity in vitro against both L3 and Mf. Interestingly,
antibodies against the homologous proteins of Ov-103 in hookworms (Ac-SAA-1) and Ov-RAL-2 in Ascaris (rAs-16), when used in vitro inhibit invasion of L3 through dog skin or caused cytotoxicity in
vitro against L3, respectively.

f

The number of ESTs were determined by BLAST-searching the L3 and mL3 EST datasets (3,510 and 5,165 entries, respectively) using each individual gene sequence. A gene was considered up-regulated
if the ESTs occurred at least 5 times in a particular stage.

d

Immunogenicity based on data obtained from protected humans, putatively immune individuals (PI), infected individuals who developed concomitant immunity (CI), and/or antibodies from xL3 animal
models (xL3 mouse model, cows or chimpanzees);

c

0.2

0.2

Body wall; ES
product

0.2

Cattle anti-Ol-xL3

0.2

0.2

0.2

Immunogenicityc

Cuticle;
hypodermis;
ES product

In Mf: surface

Localizationb

Localization based on the native protein in larval stages (L3 and mL3) as determined by IEM.;

b

This Table was adapted from [45].

Score

Ov-CHI-1 (75)

Score

Novel, nematode
specific; Retinoid
binding protein,

0.2

Score

Ov-RBP-1/Ov-FBP-1 (20/22)

Novel, nematode specific

0.2

Score

Ov-B20 (52/65)

Identity (Function)
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Antigen (kDa)
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Protection in animal models
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Ov, O. volvulus; Ol, O. lienalis; Bm, B. malayi; Wb, W. branconfti; Ls, L. sigmodontis; Av, A. viteae; Ac, A. ceylanicum; As, Ascaris Suum;; BC, block copolymer; ES, excretory–secretory product. XXX
– protective in Ov and Bm; XXX- protective in Ov and other filaria animal model (Wb, Av or Lg); XXX protective in Ov and in other nematodes.
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